Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)

SHE:300006 Revenue

Chongqing Lummy Pharmaceutical had revenue of 174.94M CNY in the quarter ending September 30, 2026, a decrease of -14.19%. This brings the company's total for the last twelve months to 720.01M, down -6.62% year-over-year. In the year 2025, Chongqing Lummy Pharmaceutical had annual revenue of 775.69M, down -2.50%. That makes Chongqing Lummy Pharmaceutical the 22,060th largest company in the world by revenue and 4,030th in China.

• Revenue (ttm): 720.01M
• Revenue Growth: -6.62%
• P/S Ratio: 14.55
• Revenue / Employee: 739.99K
• Employees: 973
• Market Cap: 10.47B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Manufacturing 590.72M 76.2%
• Pharmaceutical Distribution 152.16M 19.6%
• Service income 19.08M 2.5%
• Unallocated Other Operating Income 13.73M 1.8%

Fiscal year ended Dec 31, 2025 See the full SHE:300006 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	775.69M	-19.91M	-2.50%
Dec 31, 2024	795.60M	-99.99M	-11.17%
Dec 31, 2023	895.59M	11.01M	1.24%
Jan 1, 2023	884.59M	-340.64M	-27.80%
Dec 31, 2021	1.23B	-358.31M	-22.63%

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error